Search results
26 cze 2023 · Abstract. The treatment of advanced, radioiodine refractory, differentiated thyroid cancers (RR-DTCs) has undergone major advancements in the last decade, causing a paradigm shift in the management and prognosis of these patients.
10 kwi 2024 · The outcome was thyroid cancer (international classification of diseases, 10th revision, code C73) identified from nationwide cancer registers. In additional analyses, we investigated thyroid cancer subtypes, including papillary, follicular, medullary, and other (etable 2).
15 kwi 2024 · Involving 2562 patients diagnosed with thyroid cancer and matched with 45,184 control subjects, this extensive research utilized the French national healthcare insurance system database, focusing on T2DM patients treated with second-line antidiabetes drugs from 2006 to 2018.
28 kwi 2022 · New targeted systemic therapies have now been approved for treating patients with advanced/metastatic thyroid cancers. •. This article summarises these new options and the order in which they should be used. •. Recommendations are based on available scientific data and the authors’ collective expert opinion. •.
13 lip 2010 · Results. Six phase I, 17 phase II and 1 phase III trials with tyrosine kinase inhibitors were carried out. We found 2 pilot studies and 11 phase II trials with redifferentiation therapies, mainly in DTC. For antiproliferative approaches, three phase I and four phase II trials were found.
1 wrz 2022 · The landscape of thyroid cancer treatment has grown rapidly. Molecular profiling is the key to identify actionable targets for treatment of advanced disease. In the past decade, there have been regulatory approvals of 9 kinase inhibitors or kinase inhibitor combinations.
18 gru 2020 · Key points. Prognostic classifications currently distinguish the risk of differentiated thyroid cancer (DTC)-related death from the risk of recurrence.
